Ratings Fresenius Medical Care AG Deutsche Boerse AG

Equities

FME

DE0005785802

Market Closed - Deutsche Boerse AG Other stock markets 11:38:13 10/05/2024 pm IST			5-day change	1st Jan Change
40.3 ^EUR	+4.16%		+2.41%	+6.28%

10/05	European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3%	MT
08/05	Health Care Slips as Defensive Investors Rotate to Utilities - Health Care Roundup	DJ

Strengths

The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
The company's share price in relation to its net book value makes it look relatively cheap.
Given the positive cash flows generated by its business, the company's valuation level is an asset.

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.
The company is in debt and has limited leeway for investment
Over the past four months, analysts' average price target has been revised downwards significantly.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	ESG Refinitiv
FRESENIUS MEDICAL CARE AG	+6.28%	12.77B	-
HCA HEALTHCARE, INC.	+20.68%	85.55B	C+
CVS HEALTH CORPORATION	-29.31%	70.07B	B-
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+9.65%	29.06B	C+
LABORATORY CORPORATION OF AMERICA HOLDINGS	-8.63%	17.51B	B
FRESENIUS SE & CO. KGAA	+2.14%	17.39B	A-
QUEST DIAGNOSTICS INCORPORATED	+0.39%	15.38B	A-
REDE D'OR SÃO LUIZ S.A.	+6.47%	13.4B	B-
TENET HEALTHCARE CORPORATION	+68.23%	12.42B	C+
DAVITA INC.	+31.27%	12.06B	B-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes